{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:58:29Z","timestamp":1792979909478,"version":"4.5.0"},"reference-count":124,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T00:00:00Z","timestamp":1743292800000},"content-version":"vor","delay-in-days":88,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/j.ctarc.2025.100918","type":"journal-article","created":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T13:49:20Z","timestamp":1743601760000},"page":"100918","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Paclitaxel resistance in breast cancer: Current challenges and recent advanced therapeutic strategies"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2507-1644","authenticated-orcid":false,"given":"Heidi A.","family":"Abouzeid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loay","family":"Kassem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Abuelhana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.ctarc.2025.100918_bib0001","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s12032-023-02111-9","article-title":"Extensive review on breast cancer its etiology, progression, prognostic markers, and treatment","volume":"40","author":"Swaminathan","year":"2023","journal-title":"Med. Oncol."},{"issue":"2","key":"10.1016\/j.ctarc.2025.100918_bib0002","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.gendis.2018.05.001","article-title":"Breast cancer development and progression: risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis","volume":"5","author":"Feng","year":"2018","journal-title":"Genes. Dis."},{"key":"10.1016\/j.ctarc.2025.100918_bib0003","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-025-03502-3","article-title":"Global patterns and trends in breast cancer incidence and mortality across 185 countries","author":"Kim","year":"2025","journal-title":"Nat. Med."},{"issue":"8","key":"10.1016\/j.ctarc.2025.100918_bib0004","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.3390\/cancers15082204","article-title":"Recent advances with precision medicine treatment for breast cancer including triple-negative sub-type","volume":"15","author":"Subhan","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctarc.2025.100918_bib0005","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3389\/fonc.2018.00227","article-title":"Recent advances in the treatment of breast cancer","volume":"8","author":"Tong","year":"2018","journal-title":"Front Oncol."},{"issue":"12","key":"10.1016\/j.ctarc.2025.100918_bib0006","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1200\/JCO.2007.10.8399","article-title":"Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer","volume":"26","author":"Piccart-Gebhart","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.ctarc.2025.100918_bib0007","first-page":"2623","article-title":"Weekly paclitaxel\u2013an effective treatment for advanced breast cancer","volume":"33","author":"Kellokumpu-Lehtinen","year":"2013","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ctarc.2025.100918_bib0008","doi-asserted-by":"crossref","DOI":"10.1186\/bcr2279","article-title":"Breast tumor heterogeneity: causes and consequences","volume":"11","author":"Polyak","year":"2009","journal-title":"Breast Cancer Res."},{"issue":"56","key":"10.1016\/j.ctarc.2025.100918_bib0009","doi-asserted-by":"crossref","first-page":"9075","DOI":"10.1038\/sj.onc.1207233","article-title":"Microtubule-targeted anticancer agents and apoptosis","volume":"22","author":"Bhalla","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.ctarc.2025.100918_bib0010","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/413076","article-title":"Paclitaxel and its evolving role in the management of ovarian cancer","volume":"2015","author":"Kampan","year":"2015","journal-title":"Biomed. Res. Int."},{"issue":"11","key":"10.1016\/j.ctarc.2025.100918_bib0011","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1038\/sj.onc.1207374","article-title":"The spindle checkpoint, aneuploidy, and cancer","volume":"23","author":"Bharadwaj","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.ctarc.2025.100918_bib0012","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1007\/s00204-012-0906-3","article-title":"Oxidative stress in apoptosis and cancer: an update","volume":"86","author":"Mat\u00e9s","year":"2012","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.ctarc.2025.100918_bib0013","series-title":"Paclitaxel","first-page":"47","article-title":"Taxol: mechanisms of action against cancer, an update with current research","author":"Lim","year":"2022"},{"issue":"1","key":"10.1016\/j.ctarc.2025.100918_bib0014","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/biof.5520290103","article-title":"NF-\u03bab as a potential molecular target for cancer therapy","volume":"29","author":"Lee","year":"2007","journal-title":"Biofactors"},{"issue":"24","key":"10.1016\/j.ctarc.2025.100918_bib0015","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000038508","article-title":"HER2\/PI3K\/AKT pathway in HER2-positive breast cancer: a review","volume":"103","author":"Pan","year":"2024","journal-title":"Medicine (Baltimore)"},{"issue":"39","key":"10.1016\/j.ctarc.2025.100918_bib0016","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.19105","article-title":"The role of toll-like receptor 4 in tumor microenvironment","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget."},{"key":"10.1016\/j.ctarc.2025.100918_bib0017","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1049340","article-title":"Toll-like receptor-targeted anti-tumor therapies: advances and challenges","volume":"13","author":"Yang","year":"2022","journal-title":"Front Immunol."},{"key":"10.1016\/j.ctarc.2025.100918_bib0018","article-title":"Reassessing vascular endothelial growth factor (VEGF) in anti-angiogenic cancer therapy","volume":"32","author":"Elebiyo","year":"2022","journal-title":"Cancer Treat. Res. Commun."},{"issue":"6","key":"10.1016\/j.ctarc.2025.100918_bib0019","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1634\/theoncologist.3-6-373","article-title":"Paclitaxel in breast cancer","volume":"3","author":"Perez","year":"1998","journal-title":"Oncologist"},{"issue":"10","key":"10.1016\/j.ctarc.2025.100918_bib0020","doi-asserted-by":"crossref","first-page":"764","DOI":"10.3816\/CBC.2007.n.037","article-title":"The use of taxanes in the neoadjuvant treatment of breast cancer: a review of randomized phase II\/III trials","volume":"7","author":"Tusquets","year":"2007","journal-title":"Clin. Breast Cancer"},{"issue":"16","key":"10.1016\/j.ctarc.2025.100918_bib0021","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.2165\/00003495-200464160-00008","article-title":"Paclitaxel: as adjuvant or neoadjuvant therapy in early breast cancer","volume":"64","author":"Simpson","year":"2004","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.ctarc.2025.100918_bib0022","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/PPO.0000000000000498","article-title":"Adjuvant and neoadjuvant treatment of triple-negative breast cancer with chemotherapy","volume":"27","author":"Marra","year":"2021","journal-title":"The Cancer J."},{"issue":"16","key":"10.1016\/j.ctarc.2025.100918_bib0023","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1200\/JCO.2005.10.517","article-title":"Paclitaxel after Doxorubicin plus cyclophosphamide As adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28","volume":"23","author":"Mamounas","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2025.100918_bib0024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-018-4331-8","article-title":"The 21-gene Recurrence Score\u00ae assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin-and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial)","volume":"18","author":"Penault-Llorca","year":"2018","journal-title":"BMC. Cancer"},{"issue":"8","key":"10.1016\/j.ctarc.2025.100918_bib0025","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1093\/annonc\/mdu186","article-title":"Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression","volume":"25","author":"Nitz","year":"2014","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2025.100918_bib0026","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10549-008-0047-9","article-title":"A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer","volume":"115","author":"Fountzilas","year":"2009","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ctarc.2025.100918_bib0027","doi-asserted-by":"crossref","first-page":"4061","DOI":"10.2147\/OTT.S101423","article-title":"A meta-analysis of combination therapy versus single-agent therapy in anthracycline- and taxane-pretreated metastatic breast cancer: results from nine randomized Phase III trials","volume":"9","author":"Xu","year":"2016","journal-title":"Onco. Targets Ther."},{"issue":"1","key":"10.1016\/j.ctarc.2025.100918_bib0028","article-title":"Drug resistance and the role of combination chemotherapy in improving patient outcomes","volume":"2013","author":"Yardley","year":"2013","journal-title":"Int. J. Breast Cancer"},{"issue":"6","key":"10.1016\/j.ctarc.2025.100918_bib0029","doi-asserted-by":"crossref","DOI":"10.1186\/bcr1622","article-title":"Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342","volume":"8","author":"Harris","year":"2006","journal-title":"Breast. Cancer Res."},{"issue":"10","key":"10.1016\/j.ctarc.2025.100918_bib0030","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1200\/JCO.2007.11.6699","volume":"26","author":"Seidman","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.ctarc.2025.100918_bib0031","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1200\/JCO.2014.59.5298","volume":"33","author":"Rugo","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.ctarc.2025.100918_bib0032","doi-asserted-by":"crossref","first-page":"5043","DOI":"10.1016\/j.bmc.2005.04.084","article-title":"Recent advances in tumor-targeting anticancer drug conjugates","volume":"13","author":"Jaracz","year":"2005","journal-title":"Bioorg. Med. Chem."},{"issue":"3","key":"10.1016\/j.ctarc.2025.100918_bib0033","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3390\/plants10030569","article-title":"Current perspectives on taxanes: focus on their bioactivity, delivery and combination therapy","volume":"10","author":"\u0160kubn\u00edk","year":"2021","journal-title":"Plants"},{"issue":"1","key":"10.1016\/j.ctarc.2025.100918_bib0034","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3390\/cancers12010238","article-title":"Cytoskeletal proteins in cancer and intracellular stress: a therapeutic perspective","volume":"12","author":"Ong","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctarc.2025.100918_bib0035","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.891652","article-title":"Multidrug resistance in cancer: understanding molecular mechanisms, immunoprevention and therapeutic approaches","volume":"12","author":"Emran","year":"2022","journal-title":"Front Oncol."},{"issue":"7","key":"10.1016\/j.ctarc.2025.100918_bib0036","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18071434","article-title":"An emerging role for tubulin isotypes in modulating cancer biology and chemotherapy resistance","volume":"18","author":"Parker","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.ctarc.2025.100918_bib0037","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/nrc2803","article-title":"Microtubules and resistance to tubulin-binding agents","volume":"10","author":"Kavallaris","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ctarc.2025.100918_bib0038","doi-asserted-by":"crossref","DOI":"10.1177\/117693510700300028","article-title":"The roles of \u03b2-tubulin mutations and isotype expression in acquired drug resistance","volume":"3","author":"Huzil","year":"2007","journal-title":"Cancer Inform."},{"issue":"1","key":"10.1016\/j.ctarc.2025.100918_bib0039","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2174\/187152013804487263","article-title":"Cytoskeletal alterations that confer resistance to anti-tubulin chemotherapeutics","volume":"13","author":"Kanakkanthara","year":"2013","journal-title":"Anti Cancer Agents Med. Chem."},{"issue":"1","key":"10.1016\/j.ctarc.2025.100918_bib0040","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1021\/bi051207d","article-title":"Mutations at leucine 215 of beta-tubulin affect paclitaxel sensitivity by two distinct mechanisms","volume":"45","author":"Wang","year":"2006","journal-title":"Biochemistry"},{"key":"10.1016\/j.ctarc.2025.100918_bib0041","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/117693510700300028","article-title":"The roles of beta-tubulin mutations and isotype expression in acquired drug resistance","volume":"3","author":"Huzil","year":"2007","journal-title":"Cancer Inform."},{"issue":"16","key":"10.1016\/j.ctarc.2025.100918_bib0042","first-page":"25","article-title":"Intrinsic and extrinsic factors affecting microtubule dynamics in normal and cancer cells","author":"Borys","year":"2020","journal-title":"Molecules."},{"key":"10.1016\/j.ctarc.2025.100918_bib0043","doi-asserted-by":"crossref","first-page":"7195","DOI":"10.1007\/s13277-015-3361-y","article-title":"Overexpression of stathmin is resistant to paclitaxel treatment in patients with non-small cell lung cancer","volume":"36","author":"Sun","year":"2015","journal-title":"Tumor Biol."},{"key":"10.1016\/j.ctarc.2025.100918_bib0044","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s00280-011-1696-7","article-title":"The role of Tau protein in resistance to paclitaxel","volume":"68","author":"Smoter","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ctarc.2025.100918_bib0045","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.canlet.2020.06.025","article-title":"A novel taxane, difluorovinyl-ortataxel, effectively overcomes paclitaxel-resistance in breast cancer cells","volume":"491","author":"Rong","year":"2020","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.ctarc.2025.100918_bib0046","doi-asserted-by":"crossref","first-page":"253","DOI":"10.20892\/j.issn.2095-3941.2019.0284","article-title":"ABC transporters and the hallmarks of cancer: roles in cancer aggressiveness beyond multidrug resistance","volume":"17","author":"Muriithi","year":"2020","journal-title":"Cancer Biol. Med."},{"issue":"4","key":"10.1016\/j.ctarc.2025.100918_bib0047","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/10915810600746023","article-title":"Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters","volume":"25","author":"Choudhuri","year":"2006","journal-title":"Int. J. Toxicol."},{"key":"10.1016\/j.ctarc.2025.100918_bib0048","first-page":"12","article-title":"Multidrug resistance in cancer: understanding molecular mechanisms, immunoprevention and therapeutic approaches","author":"Bin Emran","year":"2022","journal-title":"Front Oncol."},{"issue":"6","key":"10.1016\/j.ctarc.2025.100918_bib0049","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1002\/jps.21169","article-title":"ABCB1 G1199A Polymorphism and ovarian cancer response to Paclitaxel","volume":"97","author":"Gr\u00e9en","year":"2008","journal-title":"J. Pharm. Sci."},{"issue":"8","key":"10.1016\/j.ctarc.2025.100918_bib0050","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.bcp.2012.01.002","article-title":"Role of breast cancer resistance protein (BCRP\/ABCG2) in cancer drug resistance","volume":"83","author":"Natarajan","year":"2012","journal-title":"Biochem. Pharmacol."},{"issue":"11","key":"10.1016\/j.ctarc.2025.100918_bib0051","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.3390\/ijms18112362","article-title":"ABC transporters in cancer stem cells: beyond chemoresistance","volume":"18","author":"Begicevic","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.ctarc.2025.100918_bib0052","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1080\/17425255.2017.1332179","article-title":"The role of membrane transporters in ovarian cancer chemoresistance and prognosis","volume":"13","author":"Cerovska","year":"2017","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"30","key":"10.1016\/j.ctarc.2025.100918_bib0053","doi-asserted-by":"crossref","first-page":"4705","DOI":"10.2174\/1381612822666160302103646","article-title":"ABC transporters in the development of multidrug resistance in cancer therapy","volume":"22","author":"Dlugosz","year":"2016","journal-title":"Curr. Pharm. Des."},{"issue":"1\u20132","key":"10.1016\/j.ctarc.2025.100918_bib0054","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.drup.2012.02.001","article-title":"Drug resistance: still a daunting challenge to the successful treatment of AML","volume":"15","author":"Shaffer","year":"2012","journal-title":"Drug Resist. Updat."},{"issue":"1","key":"10.1016\/j.ctarc.2025.100918_bib0055","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s11658-022-00344-6","article-title":"The role of epigenetic modifications in drug resistance and treatment of breast cancer","volume":"27","author":"Karami Fath","year":"2022","journal-title":"Cell. Mol. Biol. Lett."},{"issue":"5","key":"10.1016\/j.ctarc.2025.100918_bib0056","doi-asserted-by":"crossref","first-page":"847","DOI":"10.2217\/epi.15.10","article-title":"Role of epigenetic modifications in luminal breast cancer","volume":"7","author":"Abdel-Hafiz","year":"2015","journal-title":"Epigenomics."},{"issue":"4","key":"10.1016\/j.ctarc.2025.100918_bib0057","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.ajpath.2013.04.033","article-title":"Epigenetic modifications in breast cancer and their role in personalized medicine","volume":"183","author":"Stefansson","year":"2013","journal-title":"Am. J. Pathol."},{"issue":"3","key":"10.1016\/j.ctarc.2025.100918_bib0058","doi-asserted-by":"crossref","DOI":"10.3390\/biom12030367","article-title":"The role of epigenetic modifications in Human cancers and the use of natural compounds as epidrugs: mechanistic pathways and pharmacodynamic actions","volume":"12","author":"Bouyahya","year":"2022","journal-title":"Biomolecules."},{"key":"10.1016\/j.ctarc.2025.100918_bib0059","article-title":"Targeting histone modifications in breast cancer: a precise weapon on the way","volume":"9","author":"Li","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"issue":"13","key":"10.1016\/j.ctarc.2025.100918_bib0060","doi-asserted-by":"crossref","first-page":"6577","DOI":"10.18632\/aging.204836","article-title":"Crosstalk between m6A and coding\/non-coding RNA in cancer and detection methods of m6A modification residues","volume":"15","author":"Meng","year":"2023","journal-title":"Aging (Albany. NY)"},{"issue":"1","key":"10.1016\/j.ctarc.2025.100918_bib0061","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s40164-023-00386-2","article-title":"Emerging roles of m6A RNA modification in cancer therapeutic resistance","volume":"12","author":"Liu","year":"2023","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.ctarc.2025.100918_bib0062","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.656364","article-title":"Aspects of the tumor microenvironment involved in immune resistance and drug resistance","volume":"12","author":"Khalaf","year":"2021","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.ctarc.2025.100918_bib0063","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s10585-007-9097-3","article-title":"Organ selectivity in metastasis: regulation by chemokines and their receptors","volume":"25","author":"Ben-Baruch","year":"2008","journal-title":"Clin. Exp. Metastasis"},{"issue":"9","key":"10.1016\/j.ctarc.2025.100918_bib0064","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/nm1093","article-title":"Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival","volume":"10","author":"Curiel","year":"2004","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.ctarc.2025.100918_bib0065","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nrc1256","article-title":"Tumour-educated macrophages promote tumour progression and metastasis","volume":"4","author":"Pollard","year":"2004","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.ctarc.2025.100918_bib0066","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nrc.2017.118","article-title":"EMT in cancer","volume":"18","author":"Brabletz","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ctarc.2025.100918_bib0067","series-title":"EMT as the Ultimate Survival Mechanism of Cancer Cells. in Seminars in Cancer Biology","author":"Tiwari","year":"2012"},{"issue":"10","key":"10.1016\/j.ctarc.2025.100918_bib0068","doi-asserted-by":"crossref","first-page":"5848","DOI":"10.3390\/ijms23105848","article-title":"Epithelial\u2013mesenchymal transition (EMT) 2021","volume":"23","author":"Manfioletti","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.ctarc.2025.100918_bib0069","doi-asserted-by":"crossref","first-page":"642","DOI":"10.3390\/jcm8050642","article-title":"Consequences of EMT-driven changes in the immune microenvironment of breast cancer and therapeutic response of cancer cells","volume":"8","author":"Singh","year":"2019","journal-title":"J. Clin. Med."},{"issue":"2","key":"10.1016\/j.ctarc.2025.100918_bib0070","doi-asserted-by":"crossref","DOI":"10.4161\/onci.22945","article-title":"Links between toll-like receptor 4 and breast cancer","volume":"2","author":"Ahmed","year":"2013","journal-title":"Oncoimmunology."},{"issue":"6","key":"10.1016\/j.ctarc.2025.100918_bib0071","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nri1630","article-title":"Negative regulation of toll-like receptor-mediated immune responses","volume":"5","author":"Liew","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ctarc.2025.100918_bib0072","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s00011-010-0208-2","article-title":"Important aspects of toll-like receptors, ligands and their signaling pathways","volume":"59","author":"Chang","year":"2010","journal-title":"J. Inflamm. Res."},{"issue":"5","key":"10.1016\/j.ctarc.2025.100918_bib0073","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1038\/s41388-019-1040-y","article-title":"Long noncoding RNAs and exosomal lncRNAs: classification, and mechanisms in breast cancer metastasis and drug resistance","volume":"39","author":"Yousefi","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.ctarc.2025.100918_bib0074","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.canlet.2021.09.038","article-title":"Noncoding RNAs in triple negative breast cancer: mechanisms for chemoresistance","volume":"523","author":"Xia","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ctarc.2025.100918_bib0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2022.100851","article-title":"Long non-coding RNA mediated drug resistance in breast cancer","volume":"63","author":"Singh","year":"2022","journal-title":"Drug Resist. Updat."},{"issue":"8","key":"10.1016\/j.ctarc.2025.100918_bib0076","first-page":"24","article-title":"Harnessing epigenetics for Breast cancer therapy: the role of DNA methylation, histone modifications, and MicroRNA","author":"Szczepanek","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.ctarc.2025.100918_bib0077","doi-asserted-by":"crossref","first-page":"8095","DOI":"10.3390\/ijms24098095","article-title":"Interplay between LncRNAs and microRNAs in breast cancer","volume":"24","author":"Schwarzenbach","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.ctarc.2025.100918_bib0078","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ncrna.2020.11.004","article-title":"Long non-coding RNAs in breast cancer metastasis","volume":"5","author":"Mondal","year":"2020","journal-title":"Noncoding. RNA Res."},{"issue":"8","key":"10.1016\/j.ctarc.2025.100918_bib0079","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.3390\/ijms20081924","article-title":"Long noncoding RNA and epithelial mesenchymal transition in cancer","volume":"20","author":"Gugnoni","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.ctarc.2025.100918_bib0080","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.3390\/cancers13112795","article-title":"Cell plasticity and prostate cancer: the role of epithelial\u2013mesenchymal transition in tumor progression, invasion, metastasis and cancer therapy resistance","volume":"13","author":"Papanikolaou","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"22","key":"10.1016\/j.ctarc.2025.100918_bib0081","doi-asserted-by":"crossref","first-page":"5711","DOI":"10.3390\/cancers14225711","article-title":"Circular RNAs in epithelial ovarian cancer: from biomarkers to therapeutic targets","volume":"14","author":"Qiu","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctarc.2025.100918_bib0082","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221118010","article-title":"Recent advances of non-coding RNAs in ovarian cancer prognosis and therapeutics","volume":"14","author":"Chen","year":"2022","journal-title":"Ther. Adv. Med. Oncol"},{"issue":"5","key":"10.1016\/j.ctarc.2025.100918_bib0083","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/CAD.0000000000001058","article-title":"Overexpression of circ_CELSR1 facilitates paclitaxel resistance of ovarian cancer by regulating miR-149-5p\/SIK2 axis","volume":"32","author":"Wei","year":"2021","journal-title":"Anticancer Drugs"},{"issue":"4","key":"10.1016\/j.ctarc.2025.100918_bib0084","doi-asserted-by":"crossref","first-page":"384","DOI":"10.3390\/biom14040384","article-title":"Dysregulated expression patterns of circular RNAs in cancer: uncovering molecular mechanisms and biomarker potential","volume":"14","author":"DeSouza","year":"2024","journal-title":"Biomolecules."},{"key":"10.1016\/j.ctarc.2025.100918_bib0085","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/978-981-15-0602-4_2","article-title":"Regulation of ATG and autophagy initiation","author":"Li","year":"2019","journal-title":"Autophagy Biol. Dis. Basic Sci."},{"key":"10.1016\/j.ctarc.2025.100918_bib0086","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1042\/bse0550051","article-title":"The Atg8 family: multifunctional ubiquitin-like key regulators of autophagy","volume":"55","author":"Slobodkin","year":"2013","journal-title":"Essays Biochem."},{"issue":"9","key":"10.1016\/j.ctarc.2025.100918_bib0087","doi-asserted-by":"crossref","first-page":"5271","DOI":"10.3390\/ijms23095271","article-title":"Dormancy in breast cancer, the role of autophagy, lncRNAs, miRNAs and exosomes","volume":"23","author":"Jahangiri","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.ctarc.2025.100918_bib0088","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1016\/S1470-2045(19)30026-9","article-title":"Immunotherapy and targeted therapy combinations in metastatic breast cancer","volume":"20","author":"Esteva","year":"2019","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.ctarc.2025.100918_bib0089","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1093\/annonc\/mdw260","article-title":"Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study","volume":"27","author":"Delaloge","year":"2016","journal-title":"Ann. Oncol."},{"issue":"26","key":"10.1016\/j.ctarc.2025.100918_bib0090","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ctarc.2025.100918_bib0091","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s10549-021-06143-5","article-title":"Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced\/metastatic triple-negative breast cancer","volume":"189","author":"Dent","year":"2021","journal-title":"Breast. Cancer Res. Treat."},{"issue":"19","key":"10.1016\/j.ctarc.2025.100918_bib0092","doi-asserted-by":"crossref","first-page":"4329","DOI":"10.1158\/1078-0432.CCR-24-0465","article-title":"Ipatasertib plus Paclitaxel for patients with PIK3CA\/AKT1\/PTEN-altered locally advanced unresectable or metastatic triple-negative breast cancer in the IPATunity130 Phase III trial","volume":"30","author":"Dent","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.ctarc.2025.100918_bib0093","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1200\/JCO.19.00368","article-title":"Capivasertib plus Paclitaxel versus Placebo plus Paclitaxel As first-line therapy for metastatic triple-negative breast cancer: the PAKT trial","volume":"38","author":"Schmid","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"Suppl 1","key":"10.1016\/j.ctarc.2025.100918_bib0094","article-title":"Pembrolizumab improves outcomes in early-stage and locally advanced or metastatic triple-negative breast cancer","volume":"27","author":"Jacobson","year":"2022","journal-title":"Oncologist."},{"issue":"1","key":"10.1016\/j.ctarc.2025.100918_bib0095","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13045-021-01164-5","article-title":"Combination strategies to maximize the benefits of cancer immunotherapy","volume":"14","author":"Zhu","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ctarc.2025.100918_bib0096","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101821","article-title":"Epigenetic modifications: key players in cancer heterogeneity and drug resistance","volume":"39","author":"Sadida","year":"2024","journal-title":"Transl. Oncol."},{"issue":"2","key":"10.1016\/j.ctarc.2025.100918_bib0097","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41571-019-0267-4","article-title":"Combining epigenetic drugs with other therapies for solid tumours \u2014 Past lessons and future promise","volume":"17","author":"Morel","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ctarc.2025.100918_bib0098","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10911-012-9263-3","article-title":"Epigenetics as a therapeutic target in breast cancer","volume":"17","author":"Connolly","year":"2012","journal-title":"J. Mammary Gland Biol. Neoplasia"},{"key":"10.1016\/j.ctarc.2025.100918_bib0099","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.semcancer.2020.08.009","article-title":"Epigenetic and breast cancer therapy: promising diagnostic and therapeutic applications","volume":"83","author":"Sher","year":"2022","journal-title":"Semin. Cancer Biol."},{"issue":"10","key":"10.1016\/j.ctarc.2025.100918_bib0100","doi-asserted-by":"crossref","first-page":"7689","DOI":"10.1007\/s00432-023-04721-2","article-title":"Mitotic phosphorylation of tau\/MAPT modulates cell cycle progression in prostate cancer cells","volume":"149","author":"Clementi","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.ctarc.2025.100918_bib0101","first-page":"24","article-title":"Abemaciclib, Palbociclib, and Ribociclib in real-world data: a direct comparison of first-line treatment for endocrine-receptor-positive metastatic breast cancer","author":"Cejuela","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.ctarc.2025.100918_bib0102","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.3390\/cells10061447","article-title":"The multifaceted functions of autophagy in breast cancer development and treatment","volume":"10","author":"Niklaus","year":"2021","journal-title":"Cells"},{"issue":"21","key":"10.1016\/j.ctarc.2025.100918_bib0103","first-page":"21","article-title":"Targeting autophagy in breast cancer","author":"Cocco","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.ctarc.2025.100918_bib0104","doi-asserted-by":"crossref","first-page":"9303","DOI":"10.18632\/oncotarget.14066","article-title":"Bafilomycin A1 triggers proliferative potential of senescent cancer cells in vitro and in NOD\/SCID mice","volume":"8","author":"Was","year":"2017","journal-title":"Oncotarget."},{"issue":"1","key":"10.1016\/j.ctarc.2025.100918_bib0105","doi-asserted-by":"crossref","DOI":"10.1038\/srep37052","article-title":"Bafilomycin A1 induces caspase-independent cell death in hepatocellular carcinoma cells via targeting of autophagy and MAPK pathways","volume":"6","author":"Yan","year":"2016","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.ctarc.2025.100918_bib0106","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1158\/2159-8290.CD-19-1510","article-title":"Bempegaldesleukin (NKTR-214) plus Nivolumab in patients with advanced solid tumors: phase I dose-escalation study of safety, efficacy, and immune activation (PIVOT-02)","volume":"10","author":"Diab","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ctarc.2025.100918_bib0107","article-title":"2-Deoxy-d-glucose: a novel pharmacological agent for killing hypoxic tumor cells, oxygen dependence-lowering in Covid-19, and other pharmacological activities","volume":"2023","author":"Singh","year":"2023","journal-title":"Adv. Pharmacol. Pharm. Sci."},{"key":"10.1016\/j.ctarc.2025.100918_bib0108","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114911","article-title":"Metabolic heterogeneity in TNBCs: a potential determinant of therapeutic efficacy of 2-deoxyglucose and metformin combinatory therapy","volume":"164","author":"Samuel","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.ctarc.2025.100918_bib0109","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ijpharm.2017.08.095","article-title":"Targeting energy metabolism of cancer cells: combined administration of NCL-240 and 2-DG","volume":"532","author":"Pattni","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ctarc.2025.100918_bib0110","article-title":"A tumor-targeted delivery of oral isoliquiritigenin through encapsulated zein phosphatidylcholine hybrid nanoparticles prevents triple-negative breast cancer","volume":"79","author":"Wang","year":"2023","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.ctarc.2025.100918_bib0111","first-page":"1","article-title":"Cytotoxicity of bismuth (III) dithiocarbamate derivatives by promoting a mitochondrial-dependent apoptotic pathway and suppressing MCF-7 breast adenocarcinoma cell invasion","author":"Chan","year":"2024","journal-title":"J. Biol. Inorg. Chem."},{"issue":"19","key":"10.1016\/j.ctarc.2025.100918_bib0112","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.3390\/diagnostics13193072","article-title":"The role of MicroRNAs in breast cancer and the challenges of their clinical application","volume":"13","author":"Mu\u00f1oz","year":"2023","journal-title":"Diagnostics"},{"key":"10.1016\/j.ctarc.2025.100918_bib0113","doi-asserted-by":"crossref","unstructured":"Hu T, Shi R, Gu Y, Zhou H, Fang Y, Xu T, Xu Y, Wu X, Ma L, Shu Y. Cancer-derived non-coding RNAs endow tumor microenvironment with immunosuppressive properties. Wiley Interdiscip Rev RNA. 2023 Oct 10:e1822. doi: 10.1002\/wrna.1822. Epub ahead of print. PMID: 37817381.","DOI":"10.1002\/wrna.1822"},{"key":"10.1016\/j.ctarc.2025.100918_bib0114","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.123970","article-title":"Co-delivery of siBcl-2 and PTX with mitochondria-targeted functions to overcoming multidrug resistance","volume":"654","author":"Zhang","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ctarc.2025.100918_bib0115","article-title":"Current progress in chimeric antigen receptor-modified T cells for the treatment of metastatic breast cancer","volume":"162","author":"Yin","year":"2023","journal-title":"Biomed. Pharmac. Other"},{"key":"10.1016\/j.ctarc.2025.100918_bib0116","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1018786","article-title":"CAR-T cell therapy in triple-negative breast cancer: hunting the invisible devil","volume":"13","author":"Nasiri","year":"2022","journal-title":"Front Immunol."},{"key":"10.1016\/j.ctarc.2025.100918_bib0117","doi-asserted-by":"crossref","DOI":"10.1016\/j.adcanc.2023.100090","article-title":"Recent advancement in breast cancer treatment using CAR T cell therapy:- A review","volume":"7","author":"Dey","year":"2023","journal-title":"Adv. Cancer Biol. Metastasis"},{"key":"10.1016\/j.ctarc.2025.100918_bib0118","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.addr.2020.04.010","article-title":"Delivery of CRISPR\/Cas systems for cancer gene therapy and immunotherapy","volume":"168","author":"Song","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.ctarc.2025.100918_bib0119","doi-asserted-by":"crossref","DOI":"10.1172\/JCI143780","article-title":"Overcoming innate immune barriers that impede AAV gene therapy vectors","volume":"131","author":"Muhuri","year":"2021","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ctarc.2025.100918_bib0120","first-page":"141","article-title":"Great strides in precision medicine: personalized oncology, immunotherapies, and molecular diagnostics","author":"Hays","year":"2021","journal-title":"Adv. Healthc. Through Pers. Med."},{"issue":"1","key":"10.1016\/j.ctarc.2025.100918_bib0121","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s12672-025-01884-x","article-title":"Genetic advancements in breast cancer treatment: a review","volume":"16","author":"Shokoohi","year":"2025","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.ctarc.2025.100918_bib0122","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioadv.2023.213476","article-title":"Hydroelectric actuator for 3-dimensional analysis of electrophoretic and dielectrophoretic behavior of cancer cells; suitable in diagnosis and invasion studies","volume":"151","author":"Moharamipour","year":"2023","journal-title":"Biomater. Adv."},{"key":"10.1016\/j.ctarc.2025.100918_bib0123","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.561936","article-title":"Clinical perspective of FDA approved drugs with P-glycoprotein inhibition activities for potential cancer therapeutics","volume":"10","author":"Lai","year":"2020","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2025.100918_bib0124","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1186\/s12951-022-01626-z","article-title":"Emerging nanotechnology-based therapeutics to combat multidrug-resistant cancer","volume":"20","author":"Yadav","year":"2022","journal-title":"J. Nanobiotechnology."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294225000553?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294225000553?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T15:09:53Z","timestamp":1754060993000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294225000553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":124,"alternative-id":["S2468294225000553"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2025.100918","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Paclitaxel resistance in breast cancer: Current challenges and recent advanced therapeutic strategies","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2025.100918","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100918"}}